FOXM1 Inhibition Potentiates Venetoclax-Mediated Apoptosis in Rhabdomyosarcoma

Study Background and Research Question

Rhabdomyosarcoma (RMS) is the most prevalent soft tissue sarcoma in children and adolescents, characterized by limited therapeutic progress for metastatic or relapsed disease. Despite advances in chemotherapy, RMS survivors often experience significant long-term toxicities, and intensified regimens have not improved survival outcomes. The molecular heterogeneity of RMS poses challenges for the introduction of targeted therapies. Two molecular features are consistently noted in RMS: elevated expression of the anti-apoptotic protein Bcl-2, and the oncogenic transcription factor Forkhead box protein M1 (FOXM1). Both contribute to tumor cell survival and resistance to apoptosis, a hallmark of cancer progression. The FDA-approved Bcl-2 inhibitor venetoclax (also known as ABT-199) is highly effective in hematologic malignancies but demonstrates limited activity as monotherapy in solid tumors such as RMS.

This prompted the key research question: Can targeted inhibition of FOXM1 enhance the sensitivity of RMS cells to venetoclax-induced apoptosis, and what are the molecular mechanisms underlying this effect?

Key Innovation from the Reference Study

The study by Merjaneh et al. introduces a dual-targeting strategy for RMS by combining the recently developed, non-toxic FOXM1 inhibitor RCM-1 with venetoclax. The core innovation is the demonstration that FOXM1 inhibition not only suppresses RMS cell proliferation but also potentiates venetoclax-mediated apoptosis—a significant advance given the limited efficacy of Bcl-2 inhibition alone in solid tumors. Through transcriptomic profiling, the study identifies ATPase Plasma Membrane Ca²⁺ Transporting 4 (ATP2B4) as a critical effector, regulated by FOXM1, that modulates RMS cell survival. This mechanistic insight provides a rationale for targeting calcium signaling pathways in combination with apoptotic regulators for RMS therapy (reference study).

Methods and Experimental Design Insights

The experimental approach involved both in vitro and in vivo models of RMS. Key methods included:

• Small molecule treatment: RMS cell lines were treated with RCM-1, venetoclax, or their combination to evaluate effects on cell viability, apoptosis, and proliferation.
• RNA-sequencing analysis: Used to profile transcriptomic changes uniquely associated with combination therapy, highlighting ATP2B4 downregulation.
• Gene knockdown and overexpression: siRNA-mediated ATP2B4 knockdown and overexpression systems were employed to dissect causal roles in apoptosis and tumor growth.
• Animal models: Mouse xenograft models of RMS were used to test the efficacy of combination therapy on tumor growth and apoptosis in vivo.
• Apoptosis assays: Quantitative assays such as Annexin V staining and caspase activation were used to assess cell death following treatments.

Protocol Parameters

• RCM-1 dosing: Administered at concentrations optimized for FOXM1 inhibition, based on prior mouse model studies; pretreatment ~24 hours before venetoclax.
• Venetoclax (ABT-199) dosing: Applied at concentrations effective for Bcl-2 inhibition in RMS cell lines, typically in the low nanomolar range, as established for apoptosis assays (ABT-199 resource).
• Apoptosis assessment: Annexin V/PI flow cytometry and caspase-3/7 activation after 24–48 hours of treatment to quantify cell death.
• ATP2B4 knockdown: siRNA transfection 48 hours prior to functional assays; controls included scrambled siRNA.

Core Findings and Why They Matter

The study’s central findings reveal that:

• RCM-1 alone suppresses FOXM1 activity, decreases RMS cell proliferation, and induces moderate apoptosis.
• Venetoclax monotherapy exhibits limited efficacy in RMS, consistent with prior reports in solid tumor models.
• Combination therapy with RCM-1 and venetoclax leads to synergistic inhibition of tumor growth in mouse models, marked by significantly higher apoptosis rates than either agent alone (reference study).
• Transcriptomic profiling identifies ATP2B4 as a uniquely downregulated gene with combination treatment. ATP2B4 is highly expressed in RMS cells relative to normal muscle tissue.
• Functional assays show that ATP2B4 knockdown reduces RMS cell proliferation, migration, and colony formation, and increases apoptosis, while ATP2B4 overexpression has the opposite effect.
• In vivo depletion of ATP2B4 in mouse models results in reduced tumor growth, supporting its role as a therapeutic target.

These findings underscore the potential of targeting FOXM1 and calcium signaling to sensitize RMS cells to Bcl-2 inhibition. The identification of ATP2B4 as a mediator of apoptotic resistance in RMS is particularly notable, as it opens new avenues for molecularly guided therapies that minimize off-target toxicity.

Comparison with Existing Internal Articles

Several internal articles provide context for the use of ABT-199 (Venetoclax) in apoptosis research, particularly in hematologic malignancies. For instance, the article "ABT-199 (Venetoclax): Potent, Selective Bcl-2 Inhibitor for Apoptosis Assays" details the compound’s sub-nanomolar affinity for Bcl-2 and its utility in precise, low-toxicity apoptosis assays. However, as highlighted in both the reference study and internal dossiers, venetoclax’s efficacy in solid tumors like RMS is limited unless combined with agents targeting complementary survival pathways.

Another article, "ABT-199 (Venetoclax): Selective Bcl-2 Inhibition in Hematologic Models", emphasizes the use of ABT-199 in mitochondrial apoptosis pathway research and its benchmark status in non-Hodgkin lymphoma and AML models. The present study extends these insights to RMS, demonstrating that selective Bcl-2 inhibition can be potentiated by disrupting FOXM1-driven resistance mechanisms.

Limitations and Transferability

The translational value of these findings is promising but several limitations should be considered. First, the study’s efficacy data are largely preclinical, relying on cell lines and mouse xenograft models. The pharmacokinetics, toxicity profile, and optimal dosing regimens for RCM-1 in humans remain to be established. Furthermore, while ATP2B4 emerges as a compelling molecular target, its role in human RMS and potential off-tumor effects require further validation. The ability to generalize this combination strategy to other solid tumors with high Bcl-2 and FOXM1 expression also remains an open question. Finally, the study does not explore potential mechanisms of acquired resistance to dual inhibition or the impact on the tumor microenvironment.

Research Support Resources

Researchers interested in exploring selective Bcl-2 inhibition for apoptosis assays or RMS models can utilize ABT-199 (GDC-0199), Bcl-2 inhibitor, potent and selective (SKU A8194) as a benchmark tool. This compound’s high affinity and selectivity profile make it suitable for dissecting mitochondrial apoptosis pathways and evaluating combination strategies in both hematologic and solid tumor research. For protocol guidance and mechanistic background, see the referenced internal articles above. ABT-199 is available for research use from APExBIO, and can support workflows investigating apoptotic responses in RMS and related models.